|
US2016187346A1
|
|
Pyrite shrink-film laminate as a hydroxyl radical generator
|
|
US2016002337A1
|
|
HHLA2 as a novel inhibitor of human immune system and uses thereof
|
|
US2015191730A1
|
|
Aptamer-targetted antigen delivery
|
|
US2015140038A1
|
|
Mycobacterium tuberculosis ΔESX-3 mutants
|
|
US2015057331A1
|
|
Cellular targets for HIV infection
|
|
AU2013200066A1
|
|
Effect of BRI proteins on Abeta production
|
|
US2014370495A1
|
|
Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria
|
|
AU2012201344A1
|
|
Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
|
|
AU2007202818A1
|
|
Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof
|
|
AU2006275725A1
|
|
Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
|
|
AU2006236633A1
|
|
Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
|
|
AU2006200809A1
|
|
Methods of treating cancer
|
|
AU2006208430A1
|
|
Apparatus and method for monitoring cell motility
|
|
CA2576702A1
|
|
Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells
|
|
AU2004278652A1
|
|
Antigens targeted by prevalent pathogenic T cells in type 1 diabetes and uses thereof
|
|
AU2002359385B2
|
|
A novel saitohin gene and uses of same
|
|
AU2002363632B2
|
|
PTP1B inhibitors and ligands
|
|
AU7133500A
|
|
Recombinant m. tuberculosis mycobacterium auxotrophic for leucine and vaccines using same
|
|
AU1606999A
|
|
Mouse telomerase reverse transcriptase
|
|
AU4344197A
|
|
Car, a novel coxsackievirus and adenovirus receptor
|
